

Investigation Report on China Esomeprazole Market, 2010-2019

<https://marketpublishers.com/r/I1C279B1C5EEN.html>

Date: May 2015

Pages: 30

Price: US\$ 2,000.00 (Single User License)

ID: I1C279B1C5EEN

Abstracts

Description

Digestive system disease is one of frequently-occurring diseases. According to statistics of WHO, there are at least 250 million digestive tract patients, mainly suffering from cancer.

Inhibition of gastric acid secretion is the key treatment method for peptic ulcer, duodenal ulcer and gastroesophageal reflux disease. The H⁺ / K⁺ ATP enzyme in gastric parietal cells can reduce gastric acid secretion. By inhibiting the functioning of this transporter, the drug prevents formation of gastric acid. Proton pump inhibitor, namely H⁺/K⁺-ATP enzyme, inhibits the avidity of H⁺/K⁺-ATP enzyme to block gastric acid secretion caused by any stimulation

Esomeprazole is a proton pump inhibitor that appeared on the market in 2000. It becomes popular in the market because of high bioavailability, effective and lasting inhibition of gastric acid and low toxic and side effect. Total sales revenue of Nexium (trade name of esomeprazole produced by Astra Zeneca) since it was launched is over tens of billions dollars, making it one of the most important products from Astra Zeneca. Patent No. 94190335. 4 is the most crucial patent for Nexium which expires in May 2014. To avoid time-consuming and costly patent infringement lawsuits, Astra Zeneca announced in October 2011 that generic drug manufacturers with cooperation intention needed to pay royalty before producing esomeprazole generic drugs. Though generic drugs take part of Nexium's market, Astra Zeneca can recoup the loss by charging patent royalty.

Statistics shows that there are over 120 million people suffering from enterogastric

diseases in China, which is the most in the world. Incidence of peptic ulcer is 10% while that of chronic gastritis is 30%.

Nexium produced by Astra Zeneca entered China in 2004. According to CRI's investigation in China market, the CAGR of sales revenue of esomeprazole outstepped 48% from 2005 to 2014. In 2014, the sales value in sample hospital exceeded CNY 80 million, which was spectacularly successful. By the end of 2014, Chinese market was absolutely dominated by products from Astra Zeneca.

Chongqing LUMMY Pharmaceutical Co., Ltd. applied for 4 new drug registrations with esomeprazole in 2010, which was approved in August 2013. It is estimated that market pattern of esomeprazole in China will change in 2015. In the short term Nexium produced by Astra Zeneca will still have an absolute advantage in the market, but its market share will decline in the long run.

Through this report, the readers can acquire the following information:

Sales Price of Esomeprazole (Nexium) in China Hospital Market

Major Esomeprazole Manufacturers in China

Patent Status of Esomeprazole in China

Share of Esomeprazole in Different Dosage Forms in China Hospital Market

Prospect of China Esomeprazole Market

The Following Enterprises and People Are Recommended to Purchase This Report:

Manufacturers of Digestive System Diseases Medication

Investors on China Digestive System Diseases Drug Market

Contents

1 RELEVANT CONCEPTS OF ESOMEPRAZOLE

- 1.1 Development Process and Indication
- 1.2 Sales Status on the Global Market

2 MARKET OVERVIEW OF ESOMEPRAZOLE IN CHINA, 2010-2014

- 2.1 Major Manufacturers
- 2.2 Patent Status
- 2.3 Market Size

3 INVESTIGATION ON SALES VALUE OF ESOMEPRAZOLE IN CHINA, 2010-2014

- 3.1 Total Sales Value
- 3.2 Sales Value by Region

4 INVESTIGATION ON MARKET SHARE OF MAJOR ESOMEPRAZOLE MANUFACTURERS IN CHINA, 2010-2014

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

5 INVESTIGATION ON MARKET SIZE OF ESOMEPRAZOLE BY DOSAGE FORM IN CHINA, 2010-2014

- 5.1 Market Share by Sales Value and Dosage Form
- 5.2 Market Share by Sales Volume and Dosage Form

6 REFERENCE PRICE OF ESOMEPRAZOLE PRODUCED BY DIFFERENT ENTERPRISES IN CHINA HOSPITAL MARKET

- 6.1 AstraZeneca(Wuxi)
- 6.2 AstraZeneca(Sweden)
- 6.3 Chongqing LUMMY Pharmaceutical Co., Ltd.

7 MAJOR MANUFACTURERS IN CHINA ESOMEPRAZOLE MARKET, 2011-2014

- 7.1 AstraZeneca(Wuxi)
- 7.2 AstraZeneca(Sweden)
- 7.3 Chongqing LUMMY Pharmaceutical Co., Ltd.

8 MARKET PROSPECT OF ESOMEPRAZOLE IN CHINA, 2014- 2018

- 8.1 Digestive System Disease Incidence in China
- 8.2 Status of Generic Drugs
- 8.3 Forecast on Market Size
- 8.4 Forecast on Competition Pattern

Selected Charts

SELECTED CHARTS

Chart Esomeprazole Products Approved to Market in China by 2015

Chart Sales Value of Esomeprazole in Global Market, 2010-2014

Chart Esomeprazole Products Sold in China Market

Chart Patent Status of Esomeprazole in China

Chart Sales Value of Esomeprazole in Hospital Market in China, 2010-2014

Chart Sales Value of Esomeprazole by Region in China, 2010-2014

Chart Market Share of Esomeprazole Enterprises by Sales Value in China, 2010-2014

Chart Price of Esomeprazole Produced by AstraZeneca (Wuxi) in China Hospital Market, 2014

Chart Forecast on Market Size of Hospital-use Esomeprazole in China, 2014-2018

I would like to order

Product name: Investigation Report on China Eesomeprazole Market, 2010-2019

Product link: <https://marketpublishers.com/r/l1C279B1C5EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l1C279B1C5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970